A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Prevention of Chemotherapy-induced Myelosuppression
Interventions: DRUG: ALRN-6924|DRUG: TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
Sponsor: Aileron Therapeutics, Inc.